People with COPD should not use these products in place of the short-acting bronchodilator prescribed by a healthcare provider. This article discusses OTC inhalers and why they are not recommended ...

Ohtuvayre is the first new inhaled COPD therapy approved in over two decades. COPD is a chronic inflammatory condition that ...

Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

Current guidelines recommend use of one or more long-acting inhaled bronchodilators for patients with moderate, severe, or very severe COPD. However, the initial choice of long-acting inhaled ...

Background: In contrast to asthma, the indication for bronchodilators prior to bronchoscopy in patients with COPD has not been ... did not receive any inhaled medication. Spirometry was performed ...

COPD is a progressive condition ... In cases of asthma, a doctor may ask you to start using inhaled bronchodilator medications, after which they will want to recheck your FEV1 to see if your ...

belief that Ohtuvayre's bronchodilator and non-steroidal anti-inflammatory activity can re-define the COPD treatment paradigm." The encouraging sales figures come at a time when treatment options ...

The drug has a marketing authorisation in a pressurised metered-dose inhaler (pMDI), as a maintenance dual bronchodilator to relieve symptoms in adults with COPD. Bevespi, which is taken twice ...

We are building upon our strong heritage in bronchodilator and inhaler development with ongoing clinical development programmes aimed at improving the outlook for people with COPD. COPD is a ...

When spirometry is unavailable, physicians can use the St. George’s Respiratory Questionnaire score plus peak expiratory flow ...